| Literature DB >> 34944066 |
Chih-Yu Yeh1, Wei-Han Huang1, Hung-Chi Chen1,2, Yaa-Jyuhn James Meir2,3,4.
Abstract
During the development of a multicellular organism, the specification of different cell lineages originates in a small group of pluripotent cells, the epiblasts, formed in the preimplantation embryo. The pluripotent epiblast is protected from premature differentiation until exposure to inductive cues in strictly controlled spatially and temporally organized patterns guiding fetus formation. Epiblasts cultured in vitro are embryonic stem cells (ESCs), which recapitulate the self-renewal and lineage specification properties of their endogenous counterparts. The characteristics of totipotency, although less understood than pluripotency, are becoming clearer. Recent studies have shown that a minor ESC subpopulation exhibits expanded developmental potential beyond pluripotency, displaying a characteristic reminiscent of two-cell embryo blastomeres (2CLCs). In addition, reprogramming both mouse and human ESCs in defined media can produce expanded/extended pluripotent stem cells (EPSCs) similar to but different from 2CLCs. Further, the molecular roadmaps driving the transition of various potency states have been clarified. These recent key findings will allow us to understand eutherian mammalian development by comparing the underlying differences between potency network components during development. Using the mouse as a paradigm and recent progress in human PSCs, we review the epiblast's identity acquisition during embryogenesis and their ESC counterparts regarding their pluripotent fates and beyond.Entities:
Keywords: embryo stem cell (ESC); embryonal carcinoma (EC); epiblast; epiblast stem cell (EpiSC); extended/expanded potential stem cells (EPSCs); formative cell (FC); inner cell mass (ICM); pluripotency; primitive endoderm (PrE)
Mesh:
Year: 2021 PMID: 34944066 PMCID: PMC8700150 DOI: 10.3390/cells10123558
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Figure 1Mouse preimplantation embryo development and its cell lineage decisions. (A) The cell stages leading to blastomere compaction are shown. Although both cell fates are still reversible at this stage, individual blastomeres that remain outside are highly likely to become trophectoderm, whereas the cells located inside produce ICM. (B) This cell fate adaptation largely depends on the Hippo pathway [12,13,14]. In the Hippo-off state, Yap1 translocates into the nucleus and functions together with Tead4 to express trophectoderm markers, including Cdx2 and Gata3. By contrast, in the Hippo-on state, Yap1 is degraded through the phosphorylation of Lats1/2, and the cells adopt the ICM cell fate [13,14]. Cell–cell interactions through gap junctions, focal adhesion kinase, and integrins play a significant role in the first cell lineage decision. In essence, the decision to form trophectoderm versus ICM is based on the intercellular spatial organization with the activation of specific transcriptional programs, such as master regulators and other signals. (C) The second lineage specification, reorganizing and differentiating into epiblast and hypoblast (primitive endoderm; PrE) in ICM, starts around E3.5, where the mid-blastocyst is formed. Both cell allocation and lineage marker expression in ICM determine lineage specification. Both Gata6 (the PrE marker) and Nanog (the epiblast marker) are coexpressed in all ICM cells, from the morula to the early blastocyst. Later, these markers are mutually exclusive with an antagonistic relationship to reinforce this divergent lineage event [15,16,17,18,19,20]. In addition, the FGF/MAPK signaling pathway is also believed to participate in this process. The epiblast precursors secrete FGF4, whereas the PrE precursors express its receptor, FGFR2, to repress Nanog expression through the Grb2-dependent pathway [21]. The PrE markers include Gata6, Gata4, Hex, Sox17, Sox7, Dab2, and LaminInB1. In contrast, because the epiblast precursors lack FGFR2 to respond to FGF autocrine signaling, Nanog expression is preserved to define its pluripotency. Initially, the epiblasts and PrEs are intermingled in a salt-and-pepper fashion at early E3.5. Eventually, both epiblasts and PrEs are sorted into the adjacent layer by cell movement. Ⓟ indicates the phosphate group.
Figure 2Various pluripotent and totipotent-like states and their corresponding embryonic stages. The developmental continuum of pre- and early postimplantation mouse embryos is depicted, where developmental potency decreases from left to right. Epiblasts captured in vitro correspond to different developing embryos in vivo with the expression of specific markers. The conversion between stages can be achieved by either using various media or introducing specific factor sets, depending on the particular phases of interest. EXE, extraembryonic ectoderm; DVE, distal visceral endoderm; PrE, primitive endoderm; VE, visceral endoderm; Epi, epiblast.
Figure 3The molecular roadmap of transitioning between pluripotency and 2CLC. Fu et al. depicted the roundtrip transition between pluripotency and 2CLC and vice versa [164,165]. Intriguingly, traveling between pluripotency and 2CLC adopts different mechanisms and, therefore, takes different routes. The path from pluripotency to 2CLC encounters Myc and Dnmt1 as roadblocks that suppress the pluripotent expression level and DNA methylation to impede the transition. In the return route, two gene sets are observed with different temporal expression patterns to restore the pluripotent state; i.e., the late-activated pluripotent genes closely follow the early-activated expression gene set.
Figure 4A presumptive totipotency regulatory network. Both maternal and zygotic factors need to coordinate to launch the beginning of development to maintain the totipotent-like state. As 2CLC is currently only observed in mice, we adopt mouse 2CLC as a paradigm to presume its genetic circuitry, as addressed in recently published articles [171,172,173]. (A) In the current view, the homeodomain-containing DUX transcription factor plays an essential role in governing the transient 2CLC state. The expression of DUX can be regulated by several maternal factors, e.g., NELFA/Topa and Dppa2/4 complexes. DUX activation triggers downstream events that are uniquely observed in the 2-cell embryo, including the upregulation of MERVL elements. However, the downregulation of DUX is required for further development. Thus, the Dppa2/4 heterodimer complex activates LINE-1 to form a negative feedback loop to repress DUX expression by forming the LINE-1/Kap1/Nucleolin complex (B). This regulatory network is consistent with the transient expression of DUX in the 2-cell stage engaging in developmental initiation and, in turn, relaying the totipotent network to the pluripotent circuitry. Notably, other factors may function together with DUX to define the totipotent state, since Dux knockout mice still produce fertile offspring at a sub-Mendelian rate.